首页> 外文OA文献 >Machine Learning Models Combined with Virtual Screening and Molecular Docking to Predict Human Topoisomerase I Inhibitors
【2h】

Machine Learning Models Combined with Virtual Screening and Molecular Docking to Predict Human Topoisomerase I Inhibitors

机译:机器学习模型结合虚拟筛选和分子对接,以预测人拓扑异构酶I抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this work, random forest (RF), support vector machine, k-nearest neighbor and C4.5 decision tree, were used to establish classification models for predicting whether an unknown molecule is an inhibitor of human topoisomerase I (Top1) protein. All these models have achieved satisfactory results, with total prediction accuracies from 89.70% to 97.12%. Through comparative analysis, it can be found that the RF model has the best forecasting effect. The parameters were further optimized to generate the best-performing RF model. At the same time, features selection was implemented to choose properties most relevant to the inhibition of Top1 from 189 molecular descriptors through a special RF procedure. Subsequently, a ligand-based virtual screening was performed from the Maybridge database by the optimal RF model and 596 hits were picked out. Then, 67 molecules with relative probability scores over 0.7 were selected based on the screening results. Next, the 67 molecules above were docked to Top1 using AutoDock Vina. Finally, six top-ranked molecules with binding energies less than −10.0 kcal/mol were screened out and a common backbone, which is entirely different from that of existing Top1 inhibitors reported in the literature, was found.
机译:在这项工作中,随机森林(RF),支持向量机,K近邻和C4.5决策树,用于建立分类模型预测未知的分子是否是人类的拓扑异构酶I(TOP1)蛋白的抑制剂。所有这些模型都取得了令人满意的结果,总预测精度从89.70%到97.12%。通过比较分析,可以发现RF模型具有最佳预测效果。进一步优化参数以产生最佳的RF模型。同时,实施特征选择以通过特殊的RF程序选择与189个分子描述符的TOP1抑制最相关的属性。随后,通过最佳RF模型从Maybridge数据库执行基于配体的虚拟筛选,并挑出596次命中。然后,基于筛选结果选择具有相对概率分数的67个分子。接下来,使用Autodock Vina将上述67分子停靠在Top1上。最后,筛选出六个具有粘合能量的六个倒数分子,并筛选出来的伴随着-10.0kcal / mol的常见骨干,其完全不同于文献中报告的现有TOP1抑制剂的骨干。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号